Background
==========

Wheeze and persistent cough in infants are serious respiratory symptoms that can be triggered by respiratory infections and/or a variety of environmental exposures \[[@B1]-[@B3]\]. Surfactant protein A (SFTPA) is an abundant, multifunctional protein that is secreted by airway epithelial cells and functions as part of the innate immune response. SFTPA may be critical in protecting the lungs from infectious agents and environmental exposures early in life before the acquisition of specific immunity. SFTPA neutralizes respiratory viruses such as influenza and respiratory syncytial virus (RSV) \[[@B4],[@B5]\]. SFTPA also enhances the uptake of bacteria and viruses by phagocytes \[[@B6]-[@B8]\]. In addition to its role in protecting the lungs from microorganisms, SFTPA has other important immunomodulatory functions including binding aeroallergens \[[@B9]\].

SFTPA\'s role in protection of the lungs has led to exploration of potential links between SFTPA and diseases of the respiratory tract in infants and young children. Polymorphisms within *SFTPA1*and *SFTPA2*, two functional, highly homologous *SFTPA*genes \[[@B10]-[@B12]\] have been linked to respiratory distress syndrome in infants \[[@B13]-[@B15]\], severe RSV bronchiolitis \[[@B16]\], and otitis media \[[@B17],[@B18]\]. In the present study, we used a candidate gene approach to investigate whether polymorphisms within the *SFTPA1*and *SFTPA2*genes were associated with wheeze and persistent cough during the first year of life among a prospective birth cohort at risk for developing asthma.

Methods
=======

Cohort
------

Between September 1996 and December 1998, we invited women delivering babies in six hospitals in Connecticut and Massachusetts to participate in a longitudinal study of asthma development if they had at least one other child at home under 12 years of age with physician-diagnosed asthma. Infants enrolled in the cohort were considered at risk for asthma due to their asthmatic siblings. We provide a full description of the methods elsewhere \[[@B2],[@B19]\].

Of the 1,002 infants originally enrolled, respiratory symptom data were available for the first year of life for 889. Between the third and fifth year of participation, we made a second visit to the home to collect a blood sample from our cohort subjects. The current analyses are based on a convenience sample of 355 for whom whole blood and complete respiratory symptom data were available. Nucleotide changes at amino acid (aa) 19, aa 62, and aa 133 in *SFTPA1*, and aa 223 in *SFTPA2*were significantly associated with ethnicity. To prevent identification of invalid associations due to population stratification, we restricted our haplotype analyses to the ethnic group with the largest number of subjects (221 white infants). The Yale Human Investigations Committee and institutional review boards at each participating hospital reviewed and approved the study.

Data collection
---------------

A research assistant visited the home within 4 months of the infant\'s birth in order to describe the study to the infant\'s mother, obtain written informed consent, and administer a standardized questionnaire. We collected household demographic data including maternal race and ethnicity, education and number of children; detailed information regarding infant care (e.g. breastfeeding and daycare use); and maternal health status (e.g. self-reported history of allergies or physician-diagnosed asthma). Infant respiratory symptoms were collected during quarterly telephone interviews at 6, 9 and 12 months of age at which time each mother reported on her infant\'s respiratory symptoms (number of symptom-days per month of wheeze or persistent cough) and doctor or clinic visits (month and year of visit, reason for visit, and diagnosis). Around the time of the infant\'s first birthday, the mother completed an additional phone questionnaire covering her infant\'s health status during the previous year.

Genotyping of SFTPA genes
-------------------------

DNA was extracted from whole blood using the QIAamp DNA blood minikit (Qiagen) according to the manufacturer\'s instructions. We used sequence specific primer-PCR methodology to genotype the SNPs at aa 19, aa 50, aa 62, aa 133, and aa 219 in *SFTPA1*and aa 9, aa 91, aa 223 in *SFTPA2*\[[@B20]\]. We used PCR based cRFLP as described by DiAngelo et al. \[[@B21]\] to detect polymorphisms in *SFTPA2*at aa 140.

Data analysis
-------------

Outcomes of interest were respiratory symptom frequency in the first year of life categorized as none or as 1 to 7, 8 to 14, 15 to 21, 22 to 28, or more than 28 days of persistent cough or wheeze. Between 1 and 6 months of symptom information were missing for 18 infants. Data from these infants were included in analyses based on their symptom rates. All other infants had 12 months of complete symptom data. Unadjusted associations between respiratory symptoms and selected study characteristics, SNPs, and individual *SFTPA1*or *SFTPA2*alleles were evaluated with tests for linear trend (Cochran-Armitage or Somers\' D statistic). For statistical tests involving SNPs, frequencies for the minor homozygous allele and heterozygous alleles were combined and compared to the dominant homozygous group. Observed SNP frequencies were tested for Hardy-Weinberg equilibrium by χ^2^analyses. We examined pairwise linkage disequilibrium with r^2^measures (Fig. [1](#F1){ref-type="fig"}) using PROC ALLELE of the SAS/Genetics module of SAS version 9.1 \[[@B22]\]. Allele haplotypes for *SFTPA1*and for *SFTPA2*were assigned and examined for linkage disequilibrium using PROC HAPLOTYPE \[[@B22]\]. We examined the association between haplotype and respiratory symptom frequency (as categorical variables) using ordered logistic regression. Separate analyses were conducted for each symptom and each haplotype compared to all other haplotypes. We estimated the effect of uncertainty in haplotype assignment using a regression calibration technique \[[@B18],[@B23]\] and the *SFTPA1*and *SFTPA2*haplotype probabilities obtained from PROC HAPLOTYPE. As described previously \[[@B18]\], this technique involved first creating 100 separate haplotype data sets by randomly assigning subject haplotypes based on each subject\'s haplotype probabilities. Next, 100 separate ordered logistic regression models with coefficient and variance estimates (β~i~and σ~i~^2^for the i^th^model) were fit for each haplotype of interest. The estimate of the association between the respiratory symptom and the particular haplotype of interest ( $\hat{\beta}$) was calculated as the mean of the 100 regression models. The variability of the estimate was calculated as

![Pairwise linkage disequilibrium measure (r^2^) for surfactant protein A SNPs (5 *SFTPA1*SNPs: aa 19, aa 50, aa 62, aa 133, aa 219; 4 *SFTPA2*SNPs: aa 9, aa 91 aa 140, aa 223) from 221 white infants at risk for developing asthma. Gray scale represents strength of association from white (r^2^= 0) to black (r^2^= 1). (CT and MA, 1998 -- 2000)](1471-2350-8-15-1){#F1}

$$\hat{\beta}$$

where mean ($\sigma_{i}^{2}$) is defined as the mean of the 100 logistic regression variances and var (b~i~s) is defined as the variance of the 100 logistic regression b coefficients.

Results
=======

Close to half of the 221 infants in our study experienced persistent cough (51%) or wheeze (46%) during their first year of life (Table [1](#T1){ref-type="table"}). Thirty-two percent of the infants experienced from 1 to 28 days of persistent cough, 19% experienced more than 28 days of persistent cough during their first year; 36% experienced 1 to 28 days of wheeze and 10% experienced more than 28 days of wheeze during their first year of life. Male infants and infants of asthmatic mothers were more likely to experience persistent cough and wheeze during their first year of life (Table [1](#T1){ref-type="table"}). We did not find significant associations with either persistent cough or wheeze and maternal allergies, age daycare attendance began, number of months of breastfeeding, or exposure to environmental tobacco smoke (ETS).

###### 

Unadjusted associations between personal characteristics and respiratory symptoms during the first year of life for 221 white infants at risk for developing asthma. (CT and MA, 1998 -- 2000)

                                                         **Persistent cough (days/year) (%)**   **Wheeze (days/year) (%)**                                                                                                                                                              
  ----------------------------------------- ------------ -------------------------------------- ---------------------------- ------------- -------------- -------------- ----------- ---------------- ------------ ------------ ------------- -------------- -------------- ----------- ----------------
  **Characteristic**                        **n (%)**    **0**                                  **1 -- 7**                   **8 -- 14**   **15 -- 21**   **22 -- 28**   **\> 28**   **p-value**^a^   **0**        **1 -- 7**   **8 -- 14**   **15 -- 21**   **22 -- 28**   **\> 28**   **p-value**^a^
                                                                                                                                                                                                                                                                                        
  **White infants N (%)**                   **221**      109 (49.3)                             30 (13.6)                    19 (8.6)      12 (5.4)       10 (4.5)       41 (18.6)                    119 (54.3)   49 (22.4)    17 (7.8)      7 (3.2)        6 (2.7)        21 (9.6)    
  **Gender**                                                                                                                                                                                                                                                                            
   male                                     115 (52.0)   42.6                                   14.8                         11.3          7.0            7.0            17.4        0.12             44.2         27.4         8.0           3.5            4.4            12.4        **0.005**
   female                                   106 (48.0)   56.6                                   14.3                         5.7           3.8            1.9            19.8                         58.0         17.0         7.6           2.8            0.9            6.6         
  **Maternal allergies**                                                                                                                                                                                                                                                                
   No                                       81 (36.7)    44.4                                   17.3                         8.6           3.7            2.5            23.5        0.20             52.5         21.2         10.0          3.8            2.5            10.0        0.35
   Yes                                      140 (63.4)   52.1                                   11.4                         8.6           6.4            5.7            15.7                         55.4         23.0         6.5           2.9            2.9            9.4         
  **Maternal asthma**                                                                                                                                                                                                                                                                   
   No                                       153 (69.2)   52.3                                   15.0                         9.2           5.2            2.0            16.3        **0.02**         57.2         23.7         7.9           2.6            0.7            7.9         **0.01**
   Yes                                      68 (30.7)    42.6                                   10.3                         7.4           5.9            10.3           23.5                         47.8         19.4         7.5           4.5            7.5            13.4        
  **Daycare (starting age in months)**                                                                                                                                                                                                                                                  
   1 -- 5                                   43 (19.6)    48.8                                   14.0                         9.3           2.3            7.0            18.6        0.26             55.8         14.0         11.6          2.3            4.6            11.6        0.45
   6 -- 12                                  21 (9.6)     57.1                                   9.5                          19.0          4.8            0.0            9.5                          55.0         30.0         10.0          0.0            0.0            0.5         
   None in first year                       155 (70.8)   49.0                                   14.2                         6.4           6.4            4.5            19.4                         53.9         24.0         6.5           3.9            2.6            9.1         
  **Breast feeding (duration in months)**                                                                                                                                                                                                                                               
   None                                     49 (22.3)    53.1                                   14.3                         6.1           4.1            0.0            22.4        0.25             49.0         18.4         10.2          2.0            6.1            14.3        0.15
   1 -- 5                                   57 (25.9)    49.1                                   19.3                         3.5           7.0            5.3            15.8                         57.9         19.3         3.5           3.5            1.8            14.0        
   6 -- 12                                  114 (51.8)   47.4                                   10.5                         12.3          5.3            6.1            18.4                         54.5         25.9         8.9           3.6            1.8            5.4         
  **ETS**                                                                                                                                                                                                                                                                               
   No                                       197 (89.6)   48.7                                   12.2                         9.6           5.6            4.6            19.3        0.19             55.4         20.5         8.7           3.1            3.1            9.2         0.38
   Yes                                      23 (10.4)    52.2                                   26.1                         0.0           4.4            4.4            13.0                         43.5         39.1         0.0           4.4            0.0            13.0        

^a^p-values from test for trend: Cochran-Armitage exact test (1-sided) for gender, maternal allergies, maternal asthma, Environmental Tobacco Smoke (ETS); Somer\'s D statistic (1-sided) for age when starting daycare and duration of breastfeeding. Significant p-values (p \< 0.05) in bold-face type.

Table [2](#T2){ref-type="table"} contains unadjusted associations between each of the nine candidate SNPs and persistent cough or wheeze. Individual SNPs were in Hardy-Weinberg equilibrium (p \> 0.05 for the χ^2^test). Having a C nucleotide at aa 19 in *SFTPA1*was associated with greater frequency of wheeze. The G nucleotide at aa 133 was associated with both wheeze and persistent cough during the first year of life. We did not find any significant associations between each of the nine SNPs and personal characteristics listed in Table [1](#T1){ref-type="table"}.

###### 

Unadjusted associations between SNPs from surfactant protein A alleles (*SFTPA1*,*SFTPA2*) and respiratory symptoms^a^during the first year of life for white infants at risk for developing asthma. (CT and MA, 1998 -- 2000)

                                         **Persistent cough (days/year) (%)**   **Wheeze (days/year) (%)**                                                                                                                                                              
  ------------------------- ------------ -------------------------------------- ---------------------------- ------------- -------------- -------------- ----------- ---------------- ------------ ------------ ------------- -------------- -------------- ----------- ----------------
  **Characteristic**        **n (%)**    **0**                                  **1 -- 7**                   **8 -- 14**   **15 -- 21**   **22 -- 28**   **\> 28**   **p-value**^b^   **0**        **1 -- 7**   **8 -- 14**   **15 -- 21**   **22 -- 28**   **\> 28**   **p-value**^b^
                                                                                                                                                                                                                                                                        
  **White infants N (%)**   **221**      109 (49.3)                             30 (13.6)                    19 (8.6)      12 (5.4)       10 (4.5)       41 (18.6)                    119 (54.3)   49 (22.4)    17 (7.8)      7 (3.2)        6 (2.7)        21 (9.6)    
  ***SFTPA1***^c^                                                                                                                                                                                                                                                       
   **aa 19 (rs1059047)**                                                                                                                                                                                                                                                
    CC                      1 (0.4)                                                                                                                                                                                                                                     
    CT                      42 (19.0)    46.5                                   7.0                          11.6          7.0            2.3            25.6        0.15             44.2         18.6         11.6          4.6            7.0            14.0        **0.02**
    TT                      178 (80.5)   49.7                                   14.9                         8.0           5.1            5.1            17.1                         56.6         23.1         6.9           2.9            1.7            8.7         
   **aa 50 (rs1136450)**                                                                                                                                                                                                                                                
    CC                      48 (21.4)                                                                                                                                                                                                                                   
    CG                      103 (46.0)   51.7                                   10.9                         8.2           6.1            3.4            19.7        0.50             53.4         22.6         8.9           2.7            3.4            8.9         0.51
    GG                      73 (32.6)    45.2                                   17.8                         9.6           4.1            6.8            16.4                         55.6         22.2         5.6           4.2            1.4            11.1        
   **aa 62 (rs1136451)**                                                                                                                                                                                                                                                
    GG                      5 (2.2)                                                                                                                                                                                                                                     
    AG                      61 (27.5)    45.3                                   7.8                          14.1          6.2            3.1            23.4        0.11             46.9         21.9         10.9          3.1            6.2            10.9        0.07
    AA                      156 (70.3)   51.3                                   15.6                         6.5           4.6            5.2            16.9                         57.9         21.7         6.6           3.3            1.3            9.2         
   **aa 133 (rs1059057)**                                                                                                                                                                                                                                               
    GG                      1 (0.4)                                                                                                                                                                                                                                     
    AG                      38 (16.9)    36.8                                   7.9                          13.2          7.9            2.6            31.6        **0.02**         39.5         18.4         10.5          5.3            10.5           15.8        **0.003**
    AA                      186 (82.7)   51.9                                   14.8                         7.6           4.9            4.9            15.8                         57.5         23.2         7.2           2.8            1.1            8.3         
   **aa 219 (rs4253527)**                                                                                                                                                                                                                                               
    TT                      1 (0.4)                                                                                                                                                                                                                                     
    CT                      34 (15.1)    52.9                                   11.8                         20.6          2.9            0.0            11.8        0.12             55.9         29.4         11.8          0.0            0.0            2.9         0.06
    CC                      190 (84.4)   48.7                                   13.9                         6.4           5.9            5.4            19.8                         54.0         21.1         7.0           3.9            3.2            10.8        
   ***SFTPA2***^c^                                                                                                                                                                                                                                                      
    **aa 9 (rs1059046)**                                                                                                                                                                                                                                                
    CC                      42 (18.7)                                                                                                                                                                                                                                   
    AC                      109 (48.4)   52.4                                   11.6                         9.5           4.1            3.4            19.0        0.26             55.1         21.1         8.8           2.0            3.4            9.5         0.50
    AA                      74 (32.9)    43.2                                   17.6                         6.8           8.1            6.7            17.6                         52.8         25.0         5.6           5.6            1.4            9.7         
   **aa 91 (rs17886395)**                                                                                                                                                                                                                                               
    CC                      3 (1.4)                                                                                                                                                                                                                                     
    CG                      57 (25.7)    50.8                                   8.5                          10.2          5.1            3.4            22.0        0.33             54.2         18.6         6.8           3.4            8.5            8.5         0.23
    GG                      162 (73.0)   49.1                                   15.1                         8.2           5.7            5.0            17.0                         54.8         23.6         8.3           3.2            0.6            9.6         
   **aa 140 (rs1965707)**                                                                                                                                                                                                                                               
    TT                      13 (5.8)                                                                                                                                                                                                                                    
    CT                      87 (38.8)    53.1                                   15.3                         8.2           2.0            2.0            19.4        0.15             53.1         24.5         10.2          3.1            2.0            7.1         0.24
    CC                      124 (55.4)   45.9                                   12.3                         9.0           8.2            6.6            18.0                         55.0         20.8         5.8           3.3            3.3            11.7        
   **aa 223 (rs1965708)**                                                                                                                                                                                                                                               
    AA                      7 (3.1)                                                                                                                                                                                                                                     
    AC                      71 (31.6)    54.0                                   11.8                         9.2           2.7            4.0            18.4        0.27             55.3         23.7         9.2           4.0            1.3            6.6         0.18
    CC                      147 (65.3)   46.9                                   14.5                         8.3           6.9            4.8            18.6                         53.8         21.7         7.0           2.8            3.5            11.2        

^a^N = 221 infants had data for persistent cough and N = 219 for wheeze during the first year of life. ^b^p-values from test for trend: Cochran-Armitage exact test (1-sided). Minor homozygotes and heterozygous alleles were combined and compared to the dominant homozygous group. Significant p-values (p \< 0.05) in bold-face type. ^c^SNPs were in Hardy-Weinberg equilibrium. rs numbers are given in parentheses next to each amino acid.

By convention, *SFTPA1*and *SFTPA2*allele haplotypes are denoted by 6A^n^and 1A^m^respectively \[[@B17],[@B21]\]. The estimated frequency of each allele haplotype is given in Table [3](#T3){ref-type="table"}. The five SNPs in *SFTPA1*were in linkage disequilibrium as were the four SNPs in *SFTPA2*(p \< 0.0001, χ^2^test of allelic associations).

###### 

Unadjusted associations between surfactant protein A (*SFTPA1*,*SFTPA2*) haplotypes and persistent cough or wheeze in the first year of life.^a^Unadjusted odds ratios (OR) and 95% confidence intervals (CI) are from ordered logistic regression models predicting symptom frequency. ^b^(CT and MA, 1998 -- 2000)

  **Allele, haplotype**^c^   **Nucleotide/amino acid**^d^   **Estimated Frequency Distribution^e^% (95% CI)**   **Persistent Cough OR (95% CI)**   **Wheeze OR (95% CI)**                                                               
  -------------------------- ------------------------------ --------------------------------------------------- ---------------------------------- ------------------------ ------------ ---------------------- ----------------------- ------------------------
  ***SFTPA1***               **aa 19**                      **aa 50**                                           **aa 62**                          **aa 133**               **aa 219**                                                  
                                                                                                                                                                                                                                        
   **6A**                    C/Ala                          C/Leu                                               G                                  G                        C/Arg        6.1% (4.0 -- 8.3)      **3.69 (1.71, 7.98)**   **4.72 (2.20, 10.11)**
   **6A**^2^                 T/Val                          G/Val                                               A                                  A                        C/Arg        54.0% (49.3 -- 58.7)   1.18 (0.63, 2.19)       1.13 (0.60, 2.14)
   **6A**^3^                 T/Val                          C/Leu                                               A                                  A                        C/Arg        25.6% (21.6 -- 29.6)   0.81 (0.49, 1.36)       0.83 (0.49, 1.40)
   **6A**^4^                 T/Val                          C/Leu                                               G                                  A                        T/Trp        6.2% (4.1 -- 8.4)      0.94 (0.44, 2.03)       0.70 (0.31, 1.60)
   **all others**                                                                                                                                                                        8%                                             
                                                                                                                                                                                                                                        
  ***SFTPA2***               **aa 9**                       **aa 91**                                           **aa 140**                         **aa 223**                                                                           
                                                                                                                                                                                                                                        
   **1A**                    C/Thr                          C/Pro                                               C                                  C/Gln                                 8.4% (6.0 -- 10.8)     1.53 (0.75, 3.14)       1.30 (0.63, 2.71)
   **1A**^0^                 A/Asn                          G/Ala                                               C                                  C/Gln                                 54.2% (49.5 -- 58.8)   1.13 (0.60, 2.13)       1.14 (0.59, 2.19)
   **1A**^1^                 C/Thr                          G/Ala                                               T                                  A/Lys                                 13.7% (10.7 -- 16.7)   0.82 (0.45, 1.48)       0.87 (0.47, 1.58)
   **1A**^2^                 C/Thr                          G/Ala                                               C                                  C/Gln                                 10.2% (7.6 -- 12.7)    0.95 (0.49, 1.84)       0.83 (0.42, 1.64)
   **1A**^3^                 A/Asn                          G/Ala                                               T                                  A/Lys                                 1.8% (0.7 -- 2.9)      0.45 (0.08, 2.48)       0.55 (0.10, 3.06)
   **1A**^5^                 C/Thr                          C/Pro                                               T                                  C/Gln                                 4.6% (2.7 -- 6.5)      0.43 (0.15, 1.23)       0.66 (0.24, 1.79)
   **1A**^6^                 C/Thr                          G/Ala                                               T                                  C/Gln                                 3.2% (1.7 -- 4.7)      1.41 (0.49, 4.05)       1.54 (0.54, 4.39)
   **all others**                                                                                                                                                                        4%                                             
                                                                                                                                                                                                                                        
  ***SFTPA*Haplotype**                                                                                                                                                                                                                  
   **6A/1A**                                                                                                                                                                             5.4% (3.2 -- 7.2)      **3.20 (1.39, 7.36)**   **3.25 (1.43, 7.37)**
   **6A**^2^**/1A**^0^                                                                                                                                                                   49.0% (44.4 -- 53.6)   1.20 (0.66, 2.19)       1.04 (0.57, 1.90)
   **6A**^2^**/1A**^2^                                                                                                                                                                   1.8% (0.6 -- 2.9)      1.43 (0.36, 5.70)       0.26 (0.03, 1.99)
   **6A**^2^**/1A**^3^                                                                                                                                                                   1.0% (0.2 -- 1.9)      0.65 (0.10, 4.39)       0.79 (0.11, 5.47)
   **6A**^3^**/1A**^0^                                                                                                                                                                   4.7% (2.8 -- 6.6)      1.16 (0.49, 2.74)       0.92 (0.37, 2.31)
   **6A**^3^**/1A**^1^                                                                                                                                                                   11.3% (8.5 -- 14.1)    1.12 (0.60, 2.08)       1.08 (0.57, 2.04)
   **6A**^3^**/1A**^2^                                                                                                                                                                   5.6% (3.6 -- 7.6)      0.93 (0.40, 2.16)       0.92 (0.39, 2.17)
   **6A**^3^**/1A**^6^                                                                                                                                                                   1.7% (0.5 -- 2.8)      0.91 (0.21, 4.07)       2.26 (0.55, 9.33)
   **6A**^4^**/1A**^5^                                                                                                                                                                   2.9% (1.4 -- 4.4)      0.28 (0.07, 1.07)       0.30 (0.08, 1.20)
   **6A**^4^**/1A**^6^                                                                                                                                                                   1.8% (0.6 -- 3.0)      1.88 (0.49, 7.16)       1.69 (0.44, 6.39)
   **Others**                                                                                                                                                                            14.9%                                          

^a^Analyses included infants with complete data for both *SFTPA*alleles and respiratory symptoms, i.e., for *SFTPA1*and persistent cough (N = 203) or wheeze (N = 202); *SFTPA2*and persistent cough (N = 205) or wheeze (N = 204); *SFTPA*and persistent cough (N = 201) or wheeze (N = 200). ^b^Separate ordered logistic regression analyses were performed for each outcome measure and each haplotype with all other haplotypes serving as the reference group in each model. All model results (ORs \[95% CI\]) include estimates of model variabillity due to ambiguity in allele haplotype assignment (see text). Number of days per year of symptoms were included in models as a 6-category variable, i.e., 0, 1--7, 8--14, 15--21, 22--28, \> 28 days. Significant results (p \< 0.05) are in bold-face type. ^c^By convention, *SFTPA1*allele haplotypes are denoted by 6A^n^and *SFTPA2*allele haplotypes by 1A^m^\[17,21\]. ^d^aa 62, aa 133 and aa 140 are silent. ^e^Estimated frequency distribution of haplotypes (mean, 95% CI) for white infants.

The most common *SFTPA1*allele haplotypes among white infants in our study population were 6A^2^, 6A^3^, 6A^4^, and 6A in order of decreasing frequency. All others made up 8% of the *SFTPA1*alleles. 1A^0^was the most common *SFTPA2*allele followed in order by 1A^1^, 1A^2^, 1A, 1A^5^, 1A^6^, and 1A^3^. All others combined made up 4% of the *SFTPA2*alleles.

Significant associations were found between specific allele haplotypes and frequency of persistent cough or wheeze during the first year of life (Table [3](#T3){ref-type="table"}). The 6A haplotype of *SFTPA1*was a risk factor for both persistent cough and wheeze: infants with this haplotype (an estimated 6% of this group of white infants) were 3.7 to 4.7 times more likely to experience an additional week of persistent cough or wheeze, respectively, during their first year than infants without this haplotype.

*SFTPA1*and *SFTPA2*alleles are known to be in strong linkage disequilibrium \[[@B24],[@B25]\]. This was also true in our population of white infants in a general test of allelic associations (p \< 0.0001, χ^2^test), although pairwise linkage disequilibrium measures (r^2^) for SNPs within *SFTPA*reveal a spectrum of associations from r^2^= 0 to 0.6 (Fig. [1](#F1){ref-type="fig"}). An examination of *SFTPA1*and *SFTPA2*alleles together indicates that infants with the 6A/1A haplotype, an estimated 5.4% of this group, were over 3 times more likely to experience an additional week of persistent cough and/or wheeze during their first year than infants without this haplotype (Table [3](#T3){ref-type="table"}).

Discussion and conclusion
=========================

Results from our study suggest that the 6A allele haplotype of *SFTPA1*and the 6A/1A haplotype of *SFTPA*are associated with increased risk for wheeze and persistent cough among infants at risk for asthma. To our knowledge, this is the first study examining the association of polymorphisms in *SFTPA*with persistent cough and wheeze in infants. Respiratory symptoms may be triggered by bacterial or viral respiratory infections or exposure to environmental contaminants. This is certainly true for children in our birth cohort \[[@B2],[@B3],[@B19]\]. As reported previously \[[@B2]\], among all children in our birth cohort, infants whose mothers reported respiratory illnesses including bronchitis, bronchiolitis, pneumonia, or croup, were 3 to 5 times more likely to experience persistent cough or wheeze in the first year of life than infants who had no respiratory illness in their first year. Among these same infants, respiratory symptoms have also been linked to household exposures such as NO~2~\[[@B3]\] and mold \[[@B2],[@B19]\].

SFTPA likely plays multiple pleiotropic roles in the pathophysiology of the lung. Evidence from animal and human studies suggests an important role for SFTPA in protecting infants and young children during microbial infections early in life. SFTPA deficient mice are impaired in their ability to clear adenovirus from the lung \[[@B24]\]. SFTPA knockout mice show delayed clearance of *Haemophilus influenzae*\[[@B25]\]. Cell culture assays indicate that SFTPA enhances phagocytosis of *H. influenzae*and *Streptococcus pneumoniae*\[[@B26]\].

Among infants, polymorphisms in *SFTPA*have been associated with severe bronchiolitis \[[@B16]\]. The 6A^2^/1A^3^haplotype was associated with increased risk of severe RSV infection (OR 10.4 95% CI 1.3--83.2) and haplotype 6A/1A was protective for severe disease (OR 0.17 95% CI 0.04--0.80). In this study of Finnish infants, cases were hospitalized infants with documented bronchilotis caused by RSV. Controls, matched on sex and age, had no history of respiratory infections requiring hospitalization, but might have had respiratory infections (and symptoms) not requiring hospitalization. Although we identified 6A/1A with increased risk for wheeze and persistent cough, it is interesting that the 6A/1A haplotype is associated with respiratory problems in both populations. Direct comparison between the two studies is difficult because of differences in study design. In our study, \"cases\" were defined by reported respiratory symptoms. Specific causal agents were not identified, and we did not use hospitalization as a requirement for inclusion. Thus, some of our study subjects could resemble Finnish cases (hospitalized for RSV) or controls (not hospitalized, but possibly suffering from respiratory infection and exhibiting respiratory symptoms).

SFTPA has been shown to bind to aeroallergens including inhalable extracts from the mold *Aspergillus fumigatus*\[[@B27]\] and from the mite *Dermatophagoides pteronyssinus*(*Der p*) \[[@B28]\]. SFTPA has also been postulated to play a role in allergic asthma \[[@B29]\]. A murine model of asthma indicates that SFTPA mRNA and protein levels increase in response to allergen challenge \[[@B30]\]. SFTPA decreases *Der p*induced lymphocyte proliferation and histamine release from the blood of atopic donors \[[@B31]\]. SFTPA has also been implicated in bronchial inflammation of sensitized mice \[[@B32]\].

All infants in our cohort have at least one sibling with asthma and one-third have asthmatic mothers (Table [1](#T1){ref-type="table"}). Two-thirds of the infants have mothers with allergies (Table [1](#T1){ref-type="table"}). The children in our cohort experienced high rates of wheeze (46%) during their first year of life (Table [1](#T1){ref-type="table"}). Among a cohort of 890 healthy infants in Connecticut and Virginia born between 1993--1996, 33% experienced an episode of wheeze during the winter months of their first year of life \[[@B34]\]. The high rate of wheeze in our study population may reflect the special nature of our cohort: all are considered to be at risk for developing asthma. Along these same lines, *SFTPA*may play a role in the pathogenesis of asthma, and infants in our cohort, by virtue of their family histories of asthma, may differ in *SFTPA1*and *SFTPA2*hapylotype distributions compared to the general population. Population based estimates of *SFTPA1*allele haplotype frequencies among white Americans are 56.2% 6A^2^, 24.3% 6A^3^, 9.3% 6A, 7.6% 6A^4^and 2.6% other \[[@B33]\]. Allele haplotype frequencies for *SFTPA2*are 53% 1A^0^, 10.2% 1A, 14.3% 1A^1^, 7.6% 1A^2^, and 14.9% all others \[[@B33]\]. With the notable exception of the *SFTPA1*allele haplotype 6A, the distribution of *SFTPA1*and *SFTPA2*haplotypes in our sample of white infants is similar to that of white Americans in the general population. The general population frequency for 6A of 9.3% is higher than the 95% confidence interval for our estimate of 6.1% (95% CI 4.0--8.3), which may indicate a true difference in frequency for this allele haplotype among our group of infants.

The functional significance of specific changes in nucleotide sequence within *SFTPA*genes has not been well studied. *SFTPA*is a member of the collectin family and recognizes carbohydrates on the surface of pathogens via their carbohydrate recognition domain \[[@B35]\]. Allele 6A is the only common haplotype in our population with an alanine at aa 19 and a G at aa 133. The SNP at aa 133 is silent, however, aa 19 is in the N terminal region of *SFTPA1*and an alanine in this region could conceivably impact binding to pathogens or aeroallergens. Further experiments are needed to identify whether amino acid changes in this region impact the biological properties of SFTPA. Alternatively, the 6A haplotype may simply be a marker for additional uncharacterized functional polymorphisms in our cohort.

Strengths of this study include the prospective study design and the well characterized demographic, illness, and environmental exposure information for the infant cohort. Mothers in this study were likely capable of accurately reporting respiratory symptoms due to their familiarity with wheeze and persistent cough in the older asthmatic child. Haplotype analyses often use the \"most likely\" haplotype and seldom include adjustments for uncertainty in haplotype assignment. We used regression calibration techniques that incorporate this uncertainty into estimates of the effect resulting in more conservative estimates of the true associations between *SFTPA*and persistent cough or wheeze during the first year of life.

Our results support the importance of SFTPA in modulating respiratory symptoms in infants. Persistent cough and wheeze may result from a variety of exposures and the multifunctional nature of SFTPA indicates that it protects the lung under a variety of conditions. The 6A/1A haplotype may have a functional role in pathogenic processes, or may be linked to unmeasured markers that are causal. Future studies should replicate these observations and examine polymorphisms within *SFTPA*among additional racial and ethnic groups.
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